

AMENDMENT

Listing of Claims

The following listing of claims replaces all previous listings or versions thereof:

- 1-12. (Canceled)
13. (Presently amended) A method of preventing metastasis of a cellular proliferative disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of 750,000 dalton hyaluronan
14. (Previously presented) The method of claim 13, wherein said hyaluron is provided in combination with one or more of a pharmaceutical carrier, adjuvant or vehicle.
15. (Previously presented) The method according to claim 13, wherein the cellular proliferative disorder is selected from the group consisting of cancers of the breast, lung, prostate, kidney, skin, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, hematopoietic system or head and neck tissue.
16. (Previously presented) The method according to claim 13, wherein the subject is a mammal.
17. (Previously presented) The method according to claim 16, wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.
18. (Previously presented) The method according to claim 13, further comprising the step of administering a chemotherapeutic agent.

19. (Previously presented) The method of claim 18, wherein the bioavailability of the chemotherapeutic agent is enhanced.
20. (Previously presented) The method according to claim 18, wherein the administration of hyaluronan is prior to or subsequent to the administration of the chemotherapeutic agent.
21. (Previously presented) The method according to claim 18, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.
22. (Previously presented) The method according to claim 21, wherein the chemotherapeutic agent is fluorouracil (5-FU).
23. (Previously presented) The method according to claim 13, wherein the administration is orally, topically, or parenterally.
24. (Previously presented) The method according to claim 23, wherein parenteral administration is by subcutaneous injection, aerosol, intravenous, intramuscular, intrathecal, intracranial, intrasternal injection or infusion techniques.
25. (Presently amended) A method of treating a cellular proliferative disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of a composition comprising 750,000 dalton hyaluronan and a chemotherapeutic agent.
26. (Previously presented) The method of claim 25, wherein said hyaluron is provided in combination with one or more of a pharmaceutical carrier, adjuvant or vehicle.

27. (Previously presented) The method according to claim 25, wherein the cellular proliferative disorder is selected from the group consisting of cancers of the breast, lung, prostate, kidney, skin, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, hematopoietic system or head and neck tissue.
28. (Previously presented) The method according to claim 25, wherein the subject is a mammal.
29. (Previously presented) The method according to claim 28, wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.
30. (Previously presented) The method according to claim 25, wherein the bioavailability of the chemotherapeutic agent is enhanced.
31. (Previously presented) The method according to claim 25, wherein the administration of hyaluronan is prior to or subsequent to the administration of the chemotherapeutic agent.
32. (Previously presented) The method according to claim 25, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.
33. (Previously presented) The method according to claim 32, wherein the chemotherapeutic agent is fluorouracil (5-FU).

34. (Previously presented) The method according to claim 25, wherein the administration is orally, topically, or parenterally.
35. (Previously presented) The method according to claim 34, wherein parenteral administration is by subcutaneous injection, aerosol, intravenous, intramuscular, intrathecal, intracranial, intrasternal injection or infusion techniques.
36. (Presently amended) A method of treating a drug resistant diseasecellular proliferative disorder in a subject in need thereof comprising the step of administering to said subject a therapeutically effective amount of 750,000 dalton hyaluronan in conjunction with a chemotherapeutic agent.
37. (Previously presented) The method of claim 36, wherein said hyaluron is provided in combination with one or more of a pharmaceutical carrier, adjuvant or vehicle.
38. (Canceled) The method according to claim 36, wherein the drug resistant disease is a cellular proliferative disorder.
39. (Previously presented) The method according to claim 36, wherein the cellular proliferative disorder is selected from the group consisting of cancers of the breast, lung, prostate, kidney, skin, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, hematopoietic system or head and neck tissue.
40. (Previously presented) The method according to claim 36, wherein the subject is a mammal.
41. (Previously presented) The method according to claim 40, wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.

42. (Previously presented) The method according to claim 36, wherein the administration of hyaluronan is prior to or subsequent to the administration of the chemotherapeutic agent.
43. (Previously presented) The method according to claim 36, wherein the bioavailability of the chemotherapeutic agent is enhanced.
44. (Previously presented) The method according to claim 36, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.
45. (Previously presented) The method according to claim 44, wherein the chemotherapeutic agent is fluorouracil (5-FU).
46. (Previously presented) The method according to claim 36, wherein the administration is orally, topically, or parenterally.
47. (Previously presented) The method according to claim 46, wherein parenteral administration is either by subcutaneous injection, aerosol, intravenous, intramuscular, intrathecal, intracranial, intrasternal injection or infusion techniques.
48. (Canceled) A composition comprising a therapeutically effective amount of hyaluronan in combination with a pharmaceutical carrier, adjuvant or vehicle.
49. (Canceled) The composition according to claim 48, further comprising a chemotherapeutic agent.

50. (Canceled) The composition according to claim 49, wherein the chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), chlorambucil (Leukeran), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), fluorouracil (5-FU), methotrexate (mexate), CPT111, etoposide, pliamycin (Mithracin) and taxanes.